EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nonseizure symptoms and broader seizure impacts in patients with Dravet syndrome and Lennox–Gastaut syndrome in clinical practice settings: Results from a multinational survey

Drishti Shah iD, Vicente Villanueva iD, Dennis Dlugos iD, Arturo Benitez iD, Yasmin Taylor iD, Stevie Olsen iD, Hannah Connolly iD, Sophie Lai iD, J Scott Andrews iD

Epilepsia Open · 2025-12 · 10 (6) · 1783-1797

DOI: 10.1002/epi4.70118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, online erschienen am 22.09.2025. Verfasst von Drishti Shah und 8 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Lennox Gastaut Syndrome, Seizures. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Development Center Americas, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the burden of Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS), including managing seizure and nonseizure symptoms, on patients and caregivers.

Methods

Data were drawn from the Adelphi Real World DS and LGS Disease Specific Programme™, a cross‐sectional survey in Asia (China, Japan), Europe (France, Germany, Italy, Spain, United Kingdom), and the United States of America between July 2022 and August 2023. Neurologists/pediatric neurologists reported demographics, clinical characteristics, and nonseizure symptoms for up to 10 consecutively consulting patients. Caregivers provided data on patient nonseizure symptoms, quality of life (QoL), satisfaction with treatment, and caregiver burden. Analyses were descriptive.

Results

Physicians ( n = 259) reported data on 547 patients with DS and 811 with LGS. Caregivers ( n = 348) provided data on 157 patients with DS and 191 with LGS. In the previous 6 months, 51% of patients with DS experienced ≥1 seizure‐related injury and 61% experienced status epilepticus. For LGS, this was 50% and 43% of patients, respectively. Rates of moderate to very severe impairment in nonseizure symptoms were reported by physicians in learning/intellect (DS 69%; LGS 78%), verbal communication (DS 69%; LGS 71%), severity of developmental delay (DS 65%; LGS 68%), overall mental status (DS 57%; LGS 67%), and nonverbal communication (DS 61%; LGS 64%). Caregivers reported moderate to very severe impairment in learning/intellect (DS 53%; LGS 67%), severity of developmental delay (DS 52%; LGS 56%), verbal communication (DS 48%; LGS 48%), and nonverbal communication (DS 42%; LGS 45%). Caregivers reported nonseizure symptoms moderately to significantly impacted QoL for 56% of patients (DS 49%; LGS 61%); satisfaction with treatment rate was low for control over cognition/memory, verbal communication, and nonverbal communication impairment. Significance In this study, considerable burden in DS and LGS management and care was driven by nonseizure symptoms, suggesting a need for treatments that manage the broad spectrum of disease symptoms. Plain Language Summary We asked doctors and caregivers to tell us about the symptoms that patients with Dravet syndrome and Lennox–Gastaut syndrome have. We asked how the symptoms affect the lives of the patients as well as the caregivers. We found that seizures have a big impact on the health and well‐being of patients and caregivers. We also found that other symptoms not caused by seizures have a big impact on patients and their caregivers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsies, MyoclonicLennox Gastaut SyndromeSeizuresHumansFemaleMaleQuality of LifeCross-Sectional StudiesCaregiversChildChild, PreschoolAdolescentAdultSurveys and QuestionnairesYoung AdultMiddle AgedCost of Illness

Stichwörter der Autor:innen

Dravet syndromeLennox–Gastaut syndromecaregiverdisease burdennonseizure symptoms

Autor:innen und Institutionen

  • Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
  • Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Member of ERN EpiCARE.
  • The Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
  • Adelphi Real World, Bollington, UK.

ORCID-Profile: Drishti Shah, Vicente Villanueva, Dennis Dlugos, Arturo Benitez, Yasmin Taylor, Stevie Olsen, Hannah Connolly, Sophie Lai, J Scott Andrews

Förderung

  • Takeda Development Center Americas, Inc.

Zitieren

APA

Shah, D., Villanueva, V., Dlugos, D., Benitez, A., Taylor, Y., Olsen, S., Connolly, H., Lai, S., & Andrews, J. S. (2025). Nonseizure symptoms and broader seizure impacts in patients with Dravet syndrome and Lennox–Gastaut syndrome in clinical practice settings: Results from a multinational survey. Epilepsia Open, 10(6), 1783-1797. https://doi.org/10.1002/epi4.70118

Vancouver

Shah D, Villanueva V, Dlugos D, Benitez A, Taylor Y, Olsen S, et al. Nonseizure symptoms and broader seizure impacts in patients with Dravet syndrome and Lennox–Gastaut syndrome in clinical practice settings: Results from a multinational survey. Epilepsia Open. 2025;10(6):1783-1797. doi:10.1002/epi4.70118

BibTeX
@article{Shah2025,
  author = {Shah, Drishti and Villanueva, Vicente and Dlugos, Dennis and Benitez, Arturo and Taylor, Yasmin and Olsen, Stevie and Connolly, Hannah and Lai, Sophie and Andrews, J Scott},
  title = {Nonseizure symptoms and broader seizure impacts in patients with Dravet syndrome and Lennox–Gastaut syndrome in clinical practice settings: Results from a multinational survey},
  journal = {Epilepsia Open},
  year = {2025},
  volume = {10},
  number = {6},
  pages = {1783--1797},
  doi = {10.1002/epi4.70118}
}
Kostenlos starten →